Granules May Be Next Private Equity Target
As EIR Obtained For Chantilly, US Facility
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Granules India has ambitions to become a vertically integrated player in cancer therapies after the company ended joint ventures for contract research and manufacturing services as well as for making bulk ibuprofen.
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.